Free Trial

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

BioMarin Pharmaceutical logo
$57.31 -1.19 (-2.03%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

Key Stats

Today's Range
$57.15
$58.73
50-Day Range
$54.08
$61.93
52-Week Range
$52.93
$93.04
Volume
907,095 shs
Average Volume
1.93 million shs
Market Capitalization
$11.00 billion
P/E Ratio
16.98
Dividend Yield
N/A
Price Target
$93.17
Consensus Rating
Moderate Buy

Company Overview

BioMarin Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

BMRN MarketRank™: 

BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 18 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioMarin Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioMarin Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioMarin Pharmaceutical is 16.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioMarin Pharmaceutical is 16.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.41.

  • Price to Earnings Growth Ratio

    BioMarin Pharmaceutical has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    BioMarin Pharmaceutical has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioMarin Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    2.71% of the float of BioMarin Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioMarin Pharmaceutical has recently decreased by 15.71%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioMarin Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    BioMarin Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.71% of the float of BioMarin Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioMarin Pharmaceutical has recently decreased by 15.71%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioMarin Pharmaceutical has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for BioMarin Pharmaceutical this week, compared to 15 articles on an average week.
  • Search Interest

    31 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.85% of the stock of BioMarin Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioMarin Pharmaceutical's insider trading history.
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN)
The stealth altcoin the financial world is underestimating
This DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.tc pixel
BioMarin Announces Resignation of Chief Accounting Officer
See More Headlines

BMRN Stock Analysis - Frequently Asked Questions

BioMarin Pharmaceutical's stock was trading at $65.73 at the beginning of the year. Since then, BMRN shares have decreased by 12.9% and is now trading at $57.2640.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. The biotechnology company earned $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 12.59% and a net margin of 21.45%.
Read the conference call transcript
.

BioMarin Pharmaceutical's top institutional shareholders include Vanguard Group Inc. (9.90%), Primecap Management Co. CA (8.21%), Dodge & Cox (7.87%) and Viking Global Investors LP (6.40%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, Cristin Hubbard, V Bryan Lawlis, Erin Burkhart and Mark J Alles.
View institutional ownership trends
.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO).

Company Calendar

Last Earnings
2/19/2025
Today
8/26/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BMRN
CIK
1048477
Employees
3,040
Year Founded
1997

Price Target and Rating

High Price Target
$126.00
Low Price Target
$65.00
Potential Upside/Downside
+59.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.37
Trailing P/E Ratio
17.36
Forward P/E Ratio
18.57
P/E Growth
0.75
Net Income
$426.86 million
Net Margins
21.45%
Pretax Margin
27.42%
Return on Equity
12.59%
Return on Assets
10.13%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
5.56
Quick Ratio
3.60

Sales & Book Value

Annual Sales
$2.85 billion
Price / Sales
3.94
Cash Flow
$3.24 per share
Price / Cash Flow
18.05
Book Value
$29.69 per share
Price / Book
1.97

Miscellaneous

Outstanding Shares
192,010,000
Free Float
190,383,000
Market Cap
$11.23 billion
Optionable
Optionable
Beta
0.18

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:BMRN) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners